EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Real-world outcomes of combined lenvatinib and anti-PD-1 in advanced melanoma: the Lenvamel study, a multicenter retrospective study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée)

Perrine Rousset iD, Charlée Nardin, Eve Maubec, Valentine Heidelberger, Alexandra Picard, Laura Troin, Emilie Gerard, Nora Kramkimel, Maud Steff-Naud, Gaëlle Quéreux, Caroline Gaudy-Marqueste, Candice Lesage und 9 weitere

The Oncologist · 2024

DOI: 10.1093/oncolo/oyae145 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Oncologist, 2024. Verfasst von Perrine Rousset und 20 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Department, University Hospital of Nice, Nice, France. Hauptthemen laut MEDLINE: Quinolines, Melanoma, Phenylurea Compounds. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Currently, treatment options for patients with advanced melanoma who experience failed immunotherapy or targeted therapy are lacking. Recent studies suggest the antitumor activity of combined pembrolizumab and lenvatinib in patients with advanced melanoma progressing on immunotherapy. Herein, we report the clinical outcomes of combined lenvatinib and a programmed cell death protein-1 inhibitor (PD-1) in this population. Materials and Methods This French multicenter real-world study was conducted between September 2020 and July 2023. The primary endpoint was the objective response rate (ORR) according to the Response Evaluation Criteria in Solid Tumours (version 1.1). Secondary variables were treatment-related adverse events (TRAEs), progression-free survival (PFS), overall survival (OS), and duration of response (DOR).

Results

Of the 67 patients included (median age, 69 years; median follow-up, 5.0 months), 85% had stage IV-M1c or M1d disease. The overall ORR was 28.4% (95% CI, 18%-41%), including 3 complete (4.5%) and 16 partial (23.9%) responses. Median DOR was 3.1 (interquartile range, 1.3-4.3) months. Median PFS and OS were 3.1 (95% CI, 2.5-3.7) and 9.8 (95% CI, 5.6-13.9) months, respectively. Grades 3-5 TRAEs occurred in 16 (24%) patients; common TRAEs were fatigue (43.3%), nausea/vomiting (26.8%), diarrhea (20.9%), and hypertension (20.9%). No treatment-related deaths occurred.

Conclusion

Our real-world study demonstrates an interesting response rate and acceptable safety profile in a population with poor prognostic factors. Our data support this treatment option for refractory melanoma, as it is not approved by the Food and Drug Administration or European Medicines Agency, and highlight the need for new strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

QuinolinesMelanomaPhenylurea CompoundsHumansMaleFemaleAgedRetrospective StudiesMiddle AgedAged, 80 and overSkin NeoplasmsAdultAntineoplastic Combined Chemotherapy ProtocolsFranceImmune Checkpoint InhibitorsAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

advanced melanomaanti-PD-1immunotherapylenvatinibreal-world

Substanzen

lenvatinibQuinolinesPhenylurea CompoundsImmune Checkpoint InhibitorspembrolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Dermatology Department, University Hospital of Nice, Nice, France.
  • Dermatology Department, University Hospital of Besançon, Université de Franche-Comté, Besançon, France.
  • AP-HP, Dermatology Department, Avicenne Hospital, Bobigny, France.
  • Dermatology Department, University Hospital of Bordeaux, Bordeaux, France.
  • AP-HP, Dermatology Department, Cochin Hospital, Paris, France.
  • Dermatology Department, CHI Aulnay-Sous-Bois, Aulnay-Sous-Bois, France.

ORCID-Profile: Perrine Rousset

Zitieren

APA

Rousset, P., Nardin, C., Maubec, E., Heidelberger, V., Picard, A., Troin, L., Gerard, E., Kramkimel, N., Steff-Naud, M., Quéreux, G., Gaudy-Marqueste, C., Lesage, C., Mignard, C., Jeudy, G., Jouary, T., Saint-Jean, M., Baroudjian, B., Archier, E., Mortier, L., …, & Montaudié, H. (2024). Real-world outcomes of combined lenvatinib and anti-PD-1 in advanced melanoma: the Lenvamel study, a multicenter retrospective study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée). The Oncologist. https://doi.org/10.1093/oncolo/oyae145

Vancouver

Rousset P, Nardin C, Maubec E, Heidelberger V, Picard A, Troin L, et al. Real-world outcomes of combined lenvatinib and anti-PD-1 in advanced melanoma: the Lenvamel study, a multicenter retrospective study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée). The Oncologist. 2024. doi:10.1093/oncolo/oyae145

BibTeX
@article{Rousset2024,
  author = {Rousset, Perrine and Nardin, Charlée and Maubec, Eve and Heidelberger, Valentine and Picard, Alexandra and Troin, Laura and Gerard, Emilie and Kramkimel, Nora and Steff-Naud, Maud and Quéreux, Gaëlle and Gaudy-Marqueste, Caroline and Lesage, Candice and Mignard, Claire and Jeudy, Géraldine and Jouary, Thomas and Saint-Jean, Mélanie and Baroudjian, Barouyr and Archier, Elodie and Mortier, Laurent and Lebbe, Céleste and Montaudié, Henri},
  title = {Real-world outcomes of combined lenvatinib and anti-PD-1 in advanced melanoma: the Lenvamel study, a multicenter retrospective study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée)},
  journal = {The Oncologist},
  year = {2024},
  doi = {10.1093/oncolo/oyae145}
}
Kostenlos starten →